SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA.
2019 novel coronavirus disease
COVID-19
Delta
New York
Omicron
SARS-CoV-2
United States
conditional logistic regression
coronavirus disease
respiratory infections
severe acute respiratory syndrome coronavirus 2
vaccine breakthrough
variants
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
pubmed:
2
9
2022
medline:
24
9
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
Recently emerged SARS-CoV-2 variants have greater potential than earlier variants to cause vaccine breakthrough infections. During emergence of the Delta and Omicron variants, a matched case-control analysis used a viral genomic sequence dataset linked with demographic and vaccination information from New York, USA, to examine associations between virus lineage and patient vaccination status, patient age, vaccine type, and time since vaccination. Case-patients were persons infected with the emerging virus lineage, and controls were persons infected with any other virus lineage. Infections in fully vaccinated and boosted persons were significantly associated with the Omicron lineage. Odds of infection with Omicron relative to Delta generally decreased with increasing patient age. A similar pattern was observed with vaccination status during Delta emergence but was not significant. Vaccines offered less protection against Omicron, thereby increasing the number of potential hosts for emerging variants.
Identifiants
pubmed: 36048774
doi: 10.3201/eid2810.221058
pmc: PMC9514330
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1990-1998Références
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
J Clin Microbiol. 2021 Nov 18;59(12):e0064921
pubmed: 34550806
Euro Surveill. 2022 Mar;27(9):
pubmed: 35241215
Nat Commun. 2022 Jan 24;13(1):460
pubmed: 35075154
Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):
pubmed: 34716263
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
BMJ. 2020 Sep 1;370:m3365
pubmed: 32873595
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
N Engl J Med. 2022 Jan 13;386(2):116-127
pubmed: 34942067
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Nature. 2022 Feb;602(7897):481-486
pubmed: 34942632
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
Med (N Y). 2022 May 13;3(5):325-334.e4
pubmed: 35399324
JAMA Netw Open. 2022 May 2;5(5):e2212906
pubmed: 35583871
Stat Med. 2007 Aug 15;26(18):3385-97
pubmed: 17149799
mSphere. 2021 Aug 25;6(4):e0024421
pubmed: 34319130
Cell. 2021 May 13;184(10):2595-2604.e13
pubmed: 33891875